Long-term	long-term	O	O	O	O
follow-up	follow-up	O	O	O	O
of	of	O	O	O	O
ifosfamide	ifosfamide	CHEMICALS	O	OTHERS	I
renal	renal	O	DISEASE	OTHERS	I
toxicity	toxicity	O	DISEASE	OTHERS	I
in	in	O	O	O	O
children	children	O	O	O	O
treated	treated	O	O	O	O
for	for	O	O	O	O
malignant	malignant	O	O	OTHERS	I
mesenchymal	mesenchymal	O	O	OTHERS	I
tumors	tumors	O	DISEASE	OTHERS	I
:	:	O	O	O	O
an	an	O	O	O	O
International	international	O	O	O	O
Society	society	O	O	O	O
of	of	O	O	O	O
Pediatric	pediatric	O	O	O	O
Oncology	oncology	O	O	O	O
report	report	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
renal	renal	O	O	O	O
function	function	O	O	O	O
of	of	O	O	O	O
74	74	O	O	O	O
children	children	O	O	O	O
with	with	O	O	O	O
malignant	malignant	O	O	OTHERS	I
mesenchymal	mesenchymal	O	O	OTHERS	I
tumors	tumors	O	DISEASE	OTHERS	I
in	in	O	O	O	O
complete	complete	O	O	O	O
remission	remission	O	O	O	O
and	and	O	O	O	O
who	who	O	O	O	O
have	have	O	O	O	O
received	received	O	O	O	O
the	the	O	O	O	O
same	same	O	O	O	O
ifosfamide	ifosfamide	CHEMICALS	O	OTHERS	I
chemotherapy	chemotherapy	O	O	O	O
protocol	protocol	O	O	O	O
(	(	O	O	O	O
International	international	O	O	O	O
Society	society	O	O	O	O
of	of	O	O	O	O
Pediatric	pediatric	O	O	O	O
Oncology	oncology	O	O	O	O
Malignant	malignant	O	DISEASE	OTHERS	I
Mesenchymal	mesenchymal	O	DISEASE	OTHERS	I
Tumor	tumor	O	DISEASE	OTHERS	I
Study	study	O	O	O	O
84	84	O	O	O	O
[	[	O	O	O	O
SIOP	siop	O	O	O	O
MMT	mmt	O	O	O	O
84	84	O	O	O	O
]	]	O	O	O	O
)	)	O	O	O	O
were	were	O	O	O	O
studied	studied	O	O	O	O
1	1	O	O	O	O
year	year	O	O	O	O
after	after	O	O	O	O
the	the	O	O	O	O
completion	completion	O	O	O	O
of	of	O	O	O	O
treatment	treatment	O	O	O	O
.	.	O	O	O	O

Total	total	O	O	O	O
cumulative	cumulative	O	O	O	O
doses	doses	O	O	O	O
were	were	O	O	O	O
36	36	O	O	O	O
or	or	O	O	O	O
60	60	O	O	O	O
g/m2	g/m2	O	O	O	O
of	of	O	O	O	O
ifosfamide	ifosfamide	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
six	six	O	O	O	O
or	or	O	O	O	O
10	10	O	O	O	O
cycles	cycles	O	O	O	O
of	of	O	O	O	O
ifosfamide	ifosfamide	CHEMICALS	O	OTHERS	I
,	,	O	O	OTHERS	I
vincristine	vincristine	CHEMICALS	O	OTHERS	I
,	,	O	O	OTHERS	I
and	and	O	O	OTHERS	I
dactinomycin	dactinomycin	O	O	OTHERS	I
[	[	O	O	O	O
IVA	iva	O	O	OTHERS	I
]	]	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

None	none	O	O	O	O
of	of	O	O	O	O
them	them	O	O	O	O
had	had	O	O	O	O
received	received	O	O	O	O
cisplatin	cisplatin	CHEMICALS	O	OTHERS	I
chemotherapy	chemotherapy	O	O	O	O
.	.	O	O	O	O

Ages	ages	O	O	O	O
ranged	ranged	O	O	O	O
from	from	O	O	O	O
4	4	O	O	O	O
months	months	O	O	O	O
to	to	O	O	O	O
17	17	O	O	O	O
years	years	O	O	O	O
;	;	O	O	O	O
58	58	O	O	O	O
patients	patients	O	O	O	O
were	were	O	O	O	O
males	males	O	O	O	O
and	and	O	O	O	O
42	42	O	O	O	O
females	females	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
most	most	O	O	O	O
common	common	O	O	O	O
primary	primary	O	O	O	O
tumor	tumor	O	DISEASE	OTHERS	I
site	site	O	O	O	O
was	was	O	O	O	O
the	the	O	O	O	O
head	head	O	O	O	O
and	and	O	O	O	O
neck	neck	O	O	O	O
.	.	O	O	O	O

Renal	renal	O	O	O	O
function	function	O	O	O	O
was	was	O	O	O	O
investigated	investigated	O	O	O	O
by	by	O	O	O	O
measuring	measuring	O	O	O	O
plasma	plasma	O	O	O	O
and	and	O	O	O	O
urinary	urinary	O	O	O	O
electrolytes	electrolytes	O	O	O	O
,	,	O	O	O	O
glucosuria	glucosuria	O	O	OTHERS	I
,	,	O	O	O	O
proteinuria	proteinuria	O	DISEASE	OTHERS	I
,	,	O	O	O	O
aminoaciduria	aminoaciduria	O	O	OTHERS	I
,	,	O	O	O	O
urinary	urinary	O	O	O	O
pH	ph	O	O	O	O
,	,	O	O	O	O
osmolarity	osmolarity	O	O	O	O
,	,	O	O	O	O
creatinine	creatinine	CHEMICALS	O	OTHERS	I
clearance	clearance	O	O	O	O
,	,	O	O	O	O
phosphate	phosphate	CHEMICALS	O	OTHERS	I
tubular	tubular	O	O	O	O
reabsorption	reabsorption	O	O	O	O
,	,	O	O	O	O
beta	beta	O	O	O	O
2	2	O	O	O	O
microglobulinuria	microglobulinuria	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
lysozymuria	lysozymuria	O	O	O	O
.	.	O	O	O	O

Fifty-eight	fifty-eight	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
78	78	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
had	had	O	O	O	O
normal	normal	O	O	O	O
renal	renal	O	O	O	O
tests	tests	O	O	O	O
,	,	O	O	O	O
whereas	whereas	O	O	O	O
16	16	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
22	22	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
had	had	O	O	O	O
renal	renal	O	O	OTHERS	I
abnormalities	abnormalities	O	O	OTHERS	I
.	.	O	O	O	O

Two	two	O	O	O	O
subsets	subsets	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
were	were	O	O	O	O
identified	identified	O	O	O	O
from	from	O	O	O	O
this	this	O	O	O	O
latter	latter	O	O	O	O
group	group	O	O	O	O
:	:	O	O	O	O
the	the	O	O	O	O
first	first	O	O	O	O
included	included	O	O	O	O
four	four	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
5	5	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
total	total	O	O	O	O
population	population	O	O	O	O
)	)	O	O	O	O
who	who	O	O	O	O
developed	developed	O	O	O	O
major	major	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
resulting	resulting	O	O	O	O
in	in	O	O	O	O
Fanconi	fanconi	O	O	OTHERS	I
's	's	O	O	OTHERS	I
syndrome	syndrome	O	O	OTHERS	I
(	(	O	O	O	O
TDFS	tdfs	O	O	OTHERS	I
)	)	O	O	O	O
;	;	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
second	second	O	O	O	O
group	group	O	O	O	O
included	included	O	O	O	O
five	five	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
elevated	elevated	O	O	O	O
beta	beta	O	O	O	O
2	2	O	O	O	O
microglobulinuria	microglobulinuria	O	O	O	O
and	and	O	O	O	O
low	low	O	O	O	O
phosphate	phosphate	CHEMICALS	O	OTHERS	I
reabsorption	reabsorption	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
remaining	remaining	O	O	O	O
seven	seven	O	O	O	O
patients	patients	O	O	O	O
had	had	O	O	O	O
isolated	isolated	O	O	O	O
beta	beta	O	O	O	O
2	2	O	O	O	O
microglobulinuria	microglobulinuria	O	O	O	O
.	.	O	O	O	O

Severe	severe	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
was	was	O	O	O	O
correlated	correlated	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
higher	higher	O	O	O	O
cumulative	cumulative	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
60	60	O	O	O	O
g/m2	g/m2	O	O	O	O
of	of	O	O	O	O
ifosfamide	ifosfamide	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
a	a	O	O	O	O
younger	younger	O	O	O	O
age	age	O	O	O	O
(	(	O	O	O	O
less	less	O	O	O	O
than	than	O	O	O	O
2	2	O	O	O	O
1/2	1/2	O	O	O	O
years	years	O	O	O	O
old	old	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
a	a	O	O	O	O
predominance	predominance	O	O	O	O
of	of	O	O	O	O
vesicoprostatic	vesicoprostatic	O	O	O	O
tumor	tumor	O	DISEASE	OTHERS	I
involvement	involvement	O	O	O	O
.	.	O	O	O	O

This	this	O	O	O	O
low	low	O	O	O	O
percentage	percentage	O	O	O	O
(	(	O	O	O	O
5	5	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
of	of	O	O	O	O
TDFS	tdfs	O	O	OTHERS	I
must	must	O	O	O	O
be	be	O	O	O	O
evaluated	evaluated	O	O	O	O
with	with	O	O	O	O
respect	respect	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
efficacy	efficacy	O	O	O	O
of	of	O	O	O	O
ifosfamide	ifosfamide	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
the	the	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
mesenchymal	mesenchymal	O	O	OTHERS	I
tumors	tumors	O	DISEASE	OTHERS	I
in	in	O	O	O	O
children	children	O	O	O	O
.	.	O	O	O	O

